Primary central nervous system lymphoma (PCNSL), a rare variant of non‐Hodgkin's
lymphoma, is characterized by distinct biological characteristics and clinical behaviors, and …

Abstract Purpose of Review The treatment of primary central nervous system lymphoma
(PCNSL) is still under debate. One of the issues is the role of rituximab in improving the …

Abstract Purpose of Review The optimal treatment for newly diagnosed and refractory or
relapsed primary central nervous system lymphoma (PCNSL) is not fully defined. We review …

Background Primary central nervous system lymphoma (PCNSL) is a rare extranodal
lymphoma localized to the central nervous system. Small single-centre studies have …

The purpose of this retrospective study was to compare the efficacy and toxicity of high‐dose
methotrexate plus temozolomide (MT regimen) and rituximab plus MT (RMT regimen) in …

Objective The optimal regimen for use of high dose-methotrexate-based chemotherapy in
primary central nervous system lymphoma is still under debate. We conducted a …

Background: Primary central nervous system lymphoma (PCNSL) is an aggressive, rare
form of Non-Hodgkin lymphoma, characterized by the absence of systemic disease. There …

Background: Venous thromboembolism (VTE) is a frequent, potentially lethal complication in
individuals with cancer. Patients with brain tumors are at particularly high risk for VTE …

Purpose of review This review focuses on the findings of recent randomized prospective
trials evaluating new therapeutic options for primary central nervous system lymphoma …

The present study aimed to investigate the curative effect of high‑dose methotrexate (HD‑
MTX) combined with teniposide (Vm26) vs. HD‑MTX alone in the treatment of primary central …